Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization

Science Signaling

Volumn 8, Issue 372, 2015, Pages

  Herhaus, Lina ^a   Perez Oliva, Ana B ^a   Cozza, Giorgio ^b   Gourlay, Robert ^a   Weidlich, Simone ^a   Campbell, David G ^a   Pinna, Lorenzo A ^b   Sapkota, Gopal P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN; CASEIN KINASE II; DOUBLE STRANDED DNA; ENZYME; HEMAGGLUTININ; HOLOENZYME; LAMIN A; LAMIN C; LEPTOMYCIN B; OTUB1 ENZYME; P53 BINDING PROTEIN 1; POLYUBIQUITIN; PROTEIN; SERINE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TYROSINE; UBIQUITIN; UNCLASSIFIED DRUG; CYSTEINE PROTEINASE; LYSINE; OTUBAIN 1 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UBE2N PROTEIN, HUMAN; UBIQUITIN CONJUGATING ENZYME;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVE SITE; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IONIZING RADIATION; MICHAELIS CONSTANT; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RADIOACTIVITY; STOICHIOMETRY; WILD TYPE; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL NUCLEUS; CYTOLOGY; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; HEK293 CELL LINE; HELA CELL LINE; KNOCKOUT MOUSE; MAMMALIAN EMBRYO; METABOLISM; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CASEIN KINASE II; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; EMBRYO, MAMMALIAN; FIBROBLASTS; HEK293 CELLS; HELA CELLS; HUMANS; IMMUNOBLOTTING; LYSINE; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; SERINE; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84928225301     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa0441     Document Type: Article

References (52)

1. T. E. Mevissen, M. K. Hospenthal, P. P. Geurink, P. R. Elliott, M. Akutsu, N. Arnaudo, R. Ekkebus, Y. Kulathu, T. Wauer, F. El Oualid, S. M. V. Freund, H. Ovaa, D. Komander, OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell 154, 169-184 (2013).
2. D. Komander, M. J. Clague, S. Urbé, Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550-563 (2009).
3. M. Y. Balakirev, S. O. Tcherniuk, M. Jaquinod, J. Chroboczek, Otubains: A new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 4, 517-522 (2003).
4. M. J. Edelmann, A. Iphöfer, M. Akutsu, M. Altun, K. di Gleria, H. B. Kramer, E. Fiebiger, S. Dhe-Paganon, B. M. Kessler, Structural basis and specificity of human otubain 1-mediated deubiquitination. Biochem. J. 418, 379 (2009).
5. T. E. Messick, N. S. Russell, A. J. Iwata, K. L. Sarachan, R. Shiekhattar, J. R. Shanks, F. E. Reyes-Turcu, K. D. Wilkinson, R. Marmorstein, Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein. J. Biol. Chem. 283, 11038-11049 (2008).
6. T. Wang, L. Yin, E. M. Cooper, M. Y. Lai, S. Dickey, C. M. Pickart, D. Fushman, K. D. Wilkinson, R. E. Cohen, C. Wolberger, Evidence for bidentate substrate binding as the basis for the K48 linkage specificity of otubain 1. J. Mol. Biol. 386, 1011-1023 (2009).
7. R. Wiener,A. T.DiBello,P.M. Lombardi,C.M. Guzzo,X. Zhang, M. J. Matunis,C. Wolberger, E2 ubiquitin-conjugating enzymes regulate the deubiquitinating activity of OTUB1. Nat. Struct. Mol. Biol. 20, 1033-1039 (2013).
8. R. Wiener, X. Zhang, T. Wang, C. Wolberger, The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature 483, 612-622 (2012).
9. Y. C. Juang, M.C. Landry, M. Sanches, V.Vittal, C.C. Leung, D. F. Ceccarelli, A. R. Mateo, J. N. Pruneda, D. Y. Mao, R. K. Szilard, S. Orlicky, M. Munro, P. S. Brzovic, R. E. Klevit, F. Sicheri, D. Durocher, OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Mol. Cell 45, 384-397 (2012).
10. Y. Sato, A. Yamagata, S. Goto-Ito, K. Kubota, R. Miyamoto, S. Nakada, S. Fukai, Molecular basis of Lys-63-linked polyubiquitination inhibition by the interaction between human deubiquitinating enzyme OTUB1 and ubiquitin-conjugating enzyme UBC13. J. Biol. Chem. 287, 25860-25868 (2012).
11. S. Li, H. Zheng, A. P. Mao, B. Zhong, Y. Li, Y. Liu, Y. Gao, Y. Ran, P. Tien, H. B. Shu, Regulation of virus-triggered signaling by OTUB1-and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. J. Biol. Chem. 285, 4291-4297 (2010).
12. V. Stanisic, A. Malovannaya, J. Qin, D. M. Lonard, B. W. O'Malley, OTU Domaincontaining ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) a and affects ERa transcriptional activity. J. Biol. Chem. 284, 16135-16145 (2009).
13. X.-X. Sun, K. B. Challagundla, M.-S. Dai, Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 31, 576-592 (2011).
14. T. Goncharov, K. Niessen, M. C. de Almagro, A. Izrael-Tomasevic, A. V. Fedorova, E. Varfolomeev, D. Arnott, K. Deshayes, D. S. Kirkpatrick, D. Vucic, OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J. 32, 1103-1114 (2013).
15. S.Nakada, I.Tai,S.Panier, A. Al-Hakim,S.-. Iemura, Y.-C. Juang, L.O'Donnell,A.Kumakubo, M. Munro, F. Sicheri, A.-C. Gingras, T. Natsume, T. Suda, D. Durocher, Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 466, 941-946 (2010).
16. L. Herhaus, M. Al-Salihi, T. Macartney, S. Weidlich, G. P. Sapkota, OTUB1 enhances TGFb signalling by inhibiting the ubiquitylation and degradation of active SMAD2/3. Nat. Commun. 4, 2519 (2013).
17. L. Herhaus, G. P. Sapkota, The emerging roles of deubiquitylating enzymes (DUBs) in the TGFb and BMP pathways. Cell. Signal. 26, 2186-2192 (2014).
18. M. J. Edelmann, H. B. Kramer, M. Altun, B. M. Kessler, Post-translational modification of the deubiquitinating enzyme otubain 1 modulates active RhoA levels and susceptibility to Yersinia invasion. FEBS J. 277, 2515-2530 (2010).
19. S. A. Wagner, P. Beli, B. T. Weinert, M. L. Nielsen, J. Cox, M. Mann, C. Choudhary, A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell. Proteomics 10, M111.013284 (2011).
20. W. Kim, E. J. Bennett, E. L. Huttlin, A. Guo, J. Li, A. Possemato, M. E. Sowa, R. Rad, J. Rush, M. J. Comb, J. W. Harper, S. P. Gygi, Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell 44, 325-340 (2011).
21. M. PozueloRubio,K. M. Geraghty, B. H. C. Wong, N. T. Wood, D. G. Campbell, N. Morrice, C. Mackintosh, 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem. J. 379, 395-408 (2004).
22. F. Meggio, L. A. Pinna, One-thousand-and-one substrates of protein kinase CK2? FASEB J. 17, 349-368 (2003).
23. R. Battistutta, G. Lolli, Structural and functional determinants of protein kinase CK2a: Facts and open questions. Mol. Cell. Biochem. 356, 67-73 (2011).
24. M. Montenarh, Cellular regulators of protein kinase CK2. Cell Tissue Res. 342, 139-146 (2010).
25. L. A. Pinna, Protein kinase CK2: A challenge to canons. J. Cell Sci. 115, 3873-3878 (2002).
26. L. A. Pinna, The raison d'être of constitutively active protein kinases: The lesson of CK2. Acc. Chem. Res. 36, 378-384 (2003).
27. D. W. Litchfield, Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15 (2003).
28. M. Ruzzene, L. A. Pinna, Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim. Biophys. Acta 1804, 499-504 (2010).
29. T. Mueller, P. Breuer, I. Schmitt, J. Walter, B. O. Evert, U. Wüllner, CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 18, 3334-3343 (2009).
30. O. W. Huang, X. Ma, J. Yin, J. Flinders, T. Maurer, N. Kayagaki, Q. Phung, I. Bosanac, D. Arnott, V. M. Dixit, S. G. Hymowitz, M. A. Starovasnik, A. G. Cochran, Phosphorylationdependent activity of the deubiquitinase DUBA. Nat. Struct. Mol. Biol. 19, 171-175 (2012).
31. J. Vogt, R. Traynor, G. P. Sapkota, The specificities of small molecule inhibitors of the TGFb and BMP pathways. Cell. Signal. 23, 1831-1842 (2011).
32. M. A. Al-Salihi, L. Herhaus, G. P. Sapkota, Regulation of the transforming growth factor b pathway by reversible ubiquitylation. Open Biol. 2, 120082 (2012).
33. J. Larsson, M. J. Goumans, L. J. Sjostrand, M. A. van Rooijen, D. Ward, P. Leveen, X. Xu, P. ten Dijke, C. L. Mummery, S. Karlsson, Abnormal angiogenesis but intact hematopoietic potential in TGF-b type I receptor-deficient mice. EMBO J. 20, 1663-1673 (2001).
34. G. Cozza, S. Sarno, M. Ruzzene, C. Girardi, A. Orzeszko, Z. Kazimierczuk, G. Zagotto, E. Bonaiuto, M. L. Di Paolo, L. A. Pinna, Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. Biochim. Biophys. Acta 1834, 1402-1409 (2013).
35. G. Di Maira, M. Salvi, G. Arrigoni,O.Marin,S.Sarno, F. Brustolon, L. A. Pinna, M.Ruzzene, Protein kinase CK2 phosphorylates and upregulates Akt//PKB. Cell Death Differ. 12, 668-677 (2005).
36. Y. Miyata, E. Nishida, CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol. Cell. Biol. 24, 4065-4074 (2004).
37. G. Cozza, C. Girardi, A. Ranchio, G. Lolli, S. Sarno, A. Orzeszko, Z. Kazimierczuk, R. Battistutta, M. Ruzzene, L. Pinna, Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: Structural features and pharmacological potential. Cell. Mol. Life Sci. 3173-3185 (2014).
38. G. Cozza, M. Mazzorana, E. Papinutto, J. Bain, M. Elliott, G. di Maira, A. Gianoncelli, M. A. Pagano, S. Sarno, M. Ruzzene, R. Battistutta, F. Meggio, S. Moro, G. Zagotto, L. A. Pinna, Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem. J. 421, 387-395 (2009).
39. R. Battistutta, Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition. Cell. Mol. Life Sci. 66, 1868-1889 (2009).
40. G. Cozza, A. Bortolato, S. Moro, How druggable is protein kinase CK2? Med. Res. Rev. 30, 419-462 (2010).
41. M. A. Pagano, J. Bain, Z. Kazimierczuk, S. Sarno, M. Ruzzene, G. Di Maira, M. Elliott, A. Orzeszko, G. Cozza, F. Meggio, L. A. Pinna, The selectivity of inhibitors of protein kinase CK2: An update. Biochem. J. 415, 353-365 (2008).
42. R. A. Bish, O. I. Fregoso, A. Piccini, M. P. Myers, Conjugation of complex polyubiquitin chains to WRNIP1. J. Proteome Res. 7, 3481-3489 (2008).
43. N. Kudo, B. Wolff, T. Sekimoto, E. P. Schreiner, Y. Yoneda, M. Yanagida, S. Horinouchi, M. Yoshida, Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 242, 540-547 (1998).
44. J. F. Soderholm, S. L. Bird, P. Kalab, Y. Sampathkumar, K.Hasegawa, M. Uehara-Bingen, K. Weis, R. Heald, Importazole, a small molecule inhibitor of the transport receptor importin-b. ACS Chem. Biol. 6, 700-708 (2011).
45. K. Yata, J. Lloyd, S. Maslen, J. Y. Bleuyard, M. Skehel, S. J. Smerdon, F. Esashi, Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. Mol. Cell 45, 371-383 (2012).
46. B. Guerra, K. Iwabuchi, O. G. Issinger, Protein kinase CK2 is required for the recruitment of 53BP1 to sites of DNA double-strand break induced by radiomimetic drugs. Cancer Lett. 345, 115-123 (2014).
47. Y. Durocher, S. Perret, A. Kamen, High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9 (2002).
48. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
49. M. A. Al-Salihi, L. Herhaus, T. Macartney, G. P. Sapkota, USP11 augments TGFb signalling by deubiquitylating ALK5. Open Biol. 2, 120063 (2012).
50. J. Vogt, K. S. Dingwell, L. Herhaus, R. Gourlay, T. Macartney, D. Campbell, J. C. Smith, G. P. Sapkota, Protein associated with SMAD1 (PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein receptors and modulates bone morphogenetic protein signalling. Open Biol. 4, 130210 (2014).
51. D. Campbell, N. Morrice, Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing. J. Biomol. Tech. 13, 119-130 (2002).
52. L. Herhaus, M. Al-Salihi, K. S. Dingwell, T. D. Cummins, L. Wasmus, J. Vogt, R. Ewan, D. Bruce, T. Macartney, S. Weidlich, J. C. Smith, G. P. Sapkota, USP15 targets ALK3/ BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. Open Biol. 4, 140065 (2014).